Viral Hepatitis Therapeutics
1. Baraclude patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5206244 (Pediatric) | BRISTOL MYERS SQUIBB | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Aug, 2015
(10 years ago) | |
| US5206244 | BRISTOL MYERS SQUIBB | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Feb, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-127) | Oct 15, 2013 |
| New Patient Population(NPP) | Oct 12, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2017 |
Drugs and Companies using ENTECAVIR ingredient
Market Authorisation Date: 29 March, 2005
Dosage: TABLET; SOLUTION
How can I launch a generic of BARACLUDE before it's drug patent expiration?
More Information on Dosage
BARACLUDE family patents
2. Daklinza patent expiration
Treatment: Method of inhibiting hepatitis c virus; Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity
DAKLINZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 6 months from now) | |
| US8629171 | BRISTOL-MYERS SQUIBB | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(5 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 7 months from now) | |
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Indication(I-727) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Dosage: TABLET
More Information on Dosage
DAKLINZA family patents
3. Hepsera patent
expiration
Treatment: Therapy in chronic hepatitis b virus infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5663159 | GILEAD | Prodrugs of phosphonates |
Sep, 2014
(11 years ago) | |
| US6451340 | GILEAD | Nucleotide analog compositions |
Jul, 2018
(7 years ago) | |
Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient
Market Authorisation Date: 20 September, 2002
Dosage: TABLET
How can I launch a generic of HEPSERA before it's drug patent expiration?
More Information on Dosage
HEPSERA family patents
4. Incivek patent expiration
Treatment: Method of treating chronic hepatitis c
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(2 years from now) | |
| US8529882 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Dosage: TABLET
More Information on Dosage
INCIVEK family patents
5. Olysio patent expiration
Treatment: Method of treating hepatitis c
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(3 years from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
6. Rebetol patent expiration
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 years ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(2 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Dosage: SOLUTION
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
7. Rebetol patent expiration
Treatment: Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin; Me...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Dosage: CAPSULE
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
8. Sovaldi patent expiration
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(3 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Dosage: PELLETS; TABLET
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
9. Tyzeka patent expiration
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotra...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| US6569837 | NOVARTIS | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct, 2020
(5 years ago) | |
| US7795238 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6566344 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6444652 | NOVARTIS | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6395716 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2011 |
| M(M-124) | Jan 28, 2016 |
Drugs and Companies using TELBIVUDINE ingredient
NCE-1 date: 25 October, 2010
Market Authorisation Date: 25 October, 2006
Dosage: TABLET; SOLUTION
More Information on Dosage
TYZEKA family patents
10. Victrelis patent expiration
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease; Treatment of chro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(1 year, 17 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(1 year, 10 months from now) | |
| US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Dosage: CAPSULE
More Information on Dosage
VICTRELIS family patents
11. Viread patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and olde...
VIREAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(7 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(7 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Pediatric Exclusivity(PED) | Sep 24, 2017 |
| M(M-95) | Oct 01, 2013 |
| New Dosage Form(NDF) | Jan 18, 2015 |
| M(M-128) | Jul 24, 2016 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Dosage: POWDER; TABLET
How can I launch a generic of VIREAD before it's drug patent expiration?
More Information on Dosage
VIREAD family patents